We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
268 result(s) found, displaying 91 to 100
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Guselkumab
-
Prescription medicine decision summaryTGA decision: Spravato (esketamine hydrochloride) is approved for the treatment of treatment resistant depression.
-
Prescription medicine registrationActive ingredients: esketamine hydrochloride.
-
-
-
-
Cancellation by sponsorRequested by Janssen-Cilag Pty Ltd
-
Cancellation by sponsorRequested by Janssen-Cilag Pty Ltd
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ERLYAND apalutamide 60 mg film-coated tablet bottle.